RT @icnsInstituto: Primeros datos de vacuna terapéutica de células dendríticas en glioblastoma: pueden aumentar la supervivencia en una par…
The DCVax®-L scientific paper is reported here: https://t.co/Xg2q4fV3iE
RT @ChrisLacoursier: $NWBO #Biotech DATA IS BETTER Than I hoped! BREATHTAKING #ASCO18 $IBB $CNCR @bradloncar #GoBoldly https://t.co/oOZFb12…
RT @AlMusella: @SGottliebFDA #gbm Dr Gottlieb, We need access to this vaccine NOW. https://t.co/q9VD8Pggb1
RT @DCell_papers: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed…
RT @AlMusella: @SGottliebFDA #gbm Dr Gottlieb, We need access to this vaccine NOW. https://t.co/q9VD8Pggb1
RT @AlMusella: @SGottliebFDA #gbm Dr Gottlieb, We need access to this vaccine NOW. https://t.co/q9VD8Pggb1
RT @AlMusella: @SGottliebFDA #gbm Dr Gottlieb, We need access to this vaccine NOW. https://t.co/q9VD8Pggb1
RT @DCell_papers: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed…
RT @DCell_papers: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed…
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. https://t.co/fI9c0HZA86
RT @HenryFordNeuro: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnose…
RT @RichFairgrieve: Sunday presentation at ASCO should keep the ball rolling. Data in journal published Tuesday was from 2017. Hopefully #N…
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma! Great work team! @IanLeeMD @SteveKalkanisMD https://t.co/eijc4jcKYi
RT @RichFairgrieve: Sunday presentation at ASCO should keep the ball rolling. Data in journal published Tuesday was from 2017. Hopefully #N…
RT @icnsInstituto: Primeros datos de vacuna terapéutica de células dendríticas en glioblastoma: pueden aumentar la supervivencia en una par…
RT @RichFairgrieve: Sunday presentation at ASCO should keep the ball rolling. Data in journal published Tuesday was from 2017. Hopefully #N…
Primeros datos de vacuna terapéutica de células dendríticas en glioblastoma: pueden aumentar la supervivencia en una parte importante de respondedores https://t.co/rOlsNmMy4A #cancer
RT @RichFairgrieve: Sunday presentation at ASCO should keep the ball rolling. Data in journal published Tuesday was from 2017. Hopefully #N…
Sunday presentation at ASCO should keep the ball rolling. Data in journal published Tuesday was from 2017. Hopefully #NWBO management talk about 2018 data which in my estimations will show at least another 3 months mOS. If so it’s a grand slam https://t.co
First results on survival from a large Phase 3 clinical trial of an autologous… https://t.co/rof92S8Tne #JTransMed
RT @CraigHorbinski: Wow, check this out. Still preliminary, but the durations of survival are pretty doggone impressive! #glioma #BrainTumo…
Published PDF of #DCVax Phase 3 interim results can be downloaded from @BioMedCentral. #BTSM https://t.co/nzxcnOJt8w
RT @CraigHorbinski: Wow, check this out. Still preliminary, but the durations of survival are pretty doggone impressive! #glioma #BrainTumo…
RT @CraigHorbinski: Wow, check this out. Still preliminary, but the durations of survival are pretty doggone impressive! #glioma #BrainTumo…
膠芽腫への自己樹状細胞ワクチンDCVax-Lの第III相試験、初期結果は「有効」?:UCLA。 https://t.co/3v3pgI5LYu
@adamandlu The trial had a 2 year enrolment hiatus due to 'economic' reasons. Reasons for exclusions are detailed here https://t.co/PS7A87HDrr Results look promising but need to see the unblinded final data
@bengoldacre a lot of publicity and excitement about this in media today but this trial has major flaws, does it not? Designed and funded by manufacturer too! An independent critical view? https://t.co/Ou75xreHsN
RT @preopticarea: This is the paper: https://t.co/ApUQiXEC8w @Lifeiskitsch #BTSM #Glioma I know it is GBM and not astrocytomas but still it…
This is the paper: https://t.co/ApUQiXEC8w @Lifeiskitsch #BTSM #Glioma I know it is GBM and not astrocytomas but still it is a very interesting breakthrough. https://t.co/YLc52P09HJ
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly... https://t.co/FMvZiP9tCf
A game changer in glioblastoma treatment? https://t.co/tYaOXqeQ2J
@MaxJacobsEdison $NWBO is hiding the primary outcome of the trial. Progression-free survival has been evaluated but not "for this publication." https://t.co/sdPj872Fta https://t.co/SyA2yyYLnX
RT @rago_carlo: #9 (I'm a few hours late, but this was actually my #9 reason...) Top-line data, a scientific publication, or a drug-combo p…
and this is the actual paper reporting the findings https://t.co/VwGwUGr4kK
RT @sentimentstock: Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials…
RT @herkyleese: @JSTBiotech Check out https://t.co/FnnKvQbDDC. $nwbo #dcvax is going to change everything.
RT @sentimentstock: Look at that long list of 69 distinguished neurosurgeons on this comprehensive article for the 2017 interim blinded dat…
The much-talked-about collaborative paper by Liau, Ashkan, Bosch et al, on the outcomes of #immunotherapy in #glioblastoma OA: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly... https://t.co/Vo
RT @CraigHorbinski: Wow, check this out. Still preliminary, but the durations of survival are pretty doggone impressive! #glioma #BrainTumo…
positive early results from clinical trial of vaccine in newly diagnosed glioblastoma: https://t.co/rTZtW7jHrY
RT @sentimentstock: Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials…
RT @sentimentstock: $NWBO First Results on survival from large P3 clinical trial of #DCVax-L in newly diagnosed glioblastoma out. #CNBC #Im…
RT @ChrisLacoursier: #Biotech #pharma #ASCO18 $NWBO #CNBC AMAZING!!!! https://t.co/oOZFb12G5t
First blinded results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (GBM) | Journal of Translational Medicine https://t.co/u3ZRm6cHb7 #Cancer
RT @celltherapy: Cue the reaction from critics and fans. $NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Tria…
RT @sentimentstock: Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials…
RT @sentimentstock: GBM patients in $NWBO's #DCVax-L trial methylated MGMT (131) had mOS of 34.7 months past surgery with a 3-year survival…
Autologous vaccine for #glioblastoma median survival 23 months in all patients (90% pts crossed over from control group to treatment ergo can't yet compare randomisation). But remember Stupp is 14 months... https://t.co/cR9wRcXUIx https://t.co/5L7FGDH9Mv
RT @sentimentstock: $NWBO 2017 shows mOS of ALL patients was 23.1. Remember, most patients crossed over to treatment. March 2017 data 2…
Wow, check this out. Still preliminary, but the durations of survival are pretty doggone impressive! #glioma #BrainTumour #Glioblastoma #vaccine https://t.co/NCDHRYypOb
RT @drugrunner99: Price should be $28.50 not 0.285 https://t.co/uOorndEkNf
RT @sentimentstock: Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials…
RT @drugrunner99: Price should be $28.50 not 0.285 https://t.co/uOorndEkNf
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma: https://t.co/GCQ3pRucHN
RT @sentimentstock: Look at that long list of 69 distinguished neurosurgeons on this comprehensive article for the 2017 interim blinded dat…
RT @herkyleese: @JSTBiotech Check out https://t.co/FnnKvQbDDC. $nwbo #dcvax is going to change everything.
RT @sentimentstock: $NWBO 2017 shows mOS of ALL patients was 23.1. Remember, most patients crossed over to treatment. March 2017 data 2…
RT @rago_carlo: Really enjoyed reading the interim $NWBO #DCVax @NorthwestBio #GBM analysis attached. Looking forward to mPFS and latest an…
RT @sentimentstock: Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials…
RT @wkovash: $NWBO https://t.co/1NRjWxhX42
RT @sentimentstock: $NWBO 2017 shows mOS of ALL patients was 23.1. Remember, most patients crossed over to treatment. March 2017 data 2…
RT @rago_carlo: Really enjoyed reading the interim $NWBO #DCVax @NorthwestBio #GBM analysis attached. Looking forward to mPFS and latest an…
Really enjoyed reading the interim $NWBO #DCVax @NorthwestBio #GBM analysis attached. Looking forward to mPFS and latest analysis, perhaps a late-breaking abstract at #ASCO18 ? Also, are there any differences between men and women? African-Americans(n=7)?
Cue the reaction from critics and fans. $NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer https://t.co/TFYEbv9VKv. The publication can be found on the JTM website at https://t.co/
RT @sentimentstock: $NWBO 2017 shows mOS of ALL patients was 23.1. Remember, most patients crossed over to treatment. March 2017 data 2…
RT @sentimentstock: Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials…
RT @rago_carlo: #9 (I'm a few hours late, but this was actually my #9 reason...) Top-line data, a scientific publication, or a drug-combo p…
RT @drugrunner99: Price should be $28.50 not 0.285 https://t.co/uOorndEkNf
RT @sentimentstock: $NWBO 2017 shows mOS of ALL patients was 23.1. Remember, most patients crossed over to treatment. March 2017 data 2…
@StephDashNash Steph, news about glioblastoma today. See links. Best. https://t.co/Pvd86PkaCc https://t.co/Ccqnu7Wxa6
RT @herkyleese: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed gl…
RT @AlMusella: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed gli…
Price should be $28.50 not 0.285 https://t.co/uOorndEkNf
RT @rago_carlo: #9 (I'm a few hours late, but this was actually my #9 reason...) Top-line data, a scientific publication, or a drug-combo p…
RT @herkyleese: @JSTBiotech Check out https://t.co/FnnKvQbDDC. $nwbo #dcvax is going to change everything.
RT @sentimentstock: $NWBO 2017 shows mOS of ALL patients was 23.1. Remember, most patients crossed over to treatment. March 2017 data 2…
#9 (I'm a few hours late, but this was actually my #9 reason...) Top-line data, a scientific publication, or a drug-combo partnership is imminent, in my opinion. https://t.co/ipIgpQXmkQ $NWBO #DCVax @NorthwestBio #ASCO18 I promise I'll be more punctual wit
RT @Sojourner618: $NWBO Pub is out! https://t.co/Ccqnu7Wxa6
RT @sentimentstock: $NWBO First Results on survival from large P3 clinical trial of #DCVax-L in newly diagnosed glioblastoma out. #CNBC #Im…
RT @justinkeister5: As Haray Caray would say....How about that!?!? #GBM $NWBO #homerunforbraincancerpatients https://t.co/VFg1Kx5YSf
RT @herkyleese: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed gl…
RT @sentimentstock: Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials…
RT @sentimentstock: GBM patients in $NWBO's #DCVax-L trial methylated MGMT (131) had mOS of 34.7 months past surgery with a 3-year survival…
RT @sentimentstock: GBM patients in $NWBO's #DCVax-L trial methylated MGMT (131) had mOS of 34.7 months past surgery with a 3-year survival…
RT @sentimentstock: $NWBO 2017 shows mOS of ALL patients was 23.1. Remember, most patients crossed over to treatment. March 2017 data 2…
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly... https://t.co/7mW0vs8ZVV
mt #translational First results on survival from a large Phase 3 clinical trial… https://t.co/Uw9Ks6Wrtv, see more https://t.co/n3pMIRVV53
Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials is poised to unveil top line data, and 2017 data is very promising. @BBCNews @FT @thesundaytimes @business @CNBCFastMoney @FoxNews h
@drsanjaygupta Trial showing very positive results for GBM patients: https://t.co/4XXwCqWNu0
$NWBO 2017 shows mOS of ALL patients was 23.1. Remember, most patients crossed over to treatment. March 2017 data 2 year survival - 46.2% 3 year survival - 25.4% What will 2018 data be if most of last year's 100 patients still alive - ARE STILL ALIVE?
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly... https://t.co/kmYRv0cQCk
First online interim results of DC Vax - looks very promising... https://t.co/eYjaYH2YW5
RT @sentimentstock: Look at that long list of 69 distinguished neurosurgeons on this comprehensive article for the 2017 interim blinded dat…